Abstract:Background: Dapagliflozin, a selective, orally active, renal sodium glucose cotransporter 2 (SGLT2) 2 inhibitor, is under investigation as a treatment of type 2 diabetes mellitus (T2DM). Dapagliflozin reduces hyperglycemia by inhibiting renal glucose reabsorption and dose-dependently increasing urinary glucose excretion, independent of insulin secretion or action.Objectives: These studies assessed the single- and multiple-dose pharmacokinetic and pharmaco dynamic properties of dapagliflozin and its major inactive metabolite, dapagliflozin 3-O-glucuronide (D3OG), in healthy subjects residing in China.Methods: In 2 identically designed, open-label, single- and multiple-dose studies (n = 14 for both studies), healthy Chinese subjects were administered oral dapagliflozin 5 or 10 mg. In both studies, subjects received a single dose on day 1 (single-dose administration period) followed by 6 once-daily doses on days 5 to 10 (multiple-dose administration period). Pharmacokinetic parameters (plasma and urinary dapagliflozin and D3OG), pharmacodynamic response (urinary glucose excretion), and tolerability were assessed.Results: Fourteen subjects completed the dapagliflozin 5-mg study, and 13 completed the dapagliflozin 10-mg study. Baseline characteristics were balanced across the two studies: 9 versus 10 men; mean age, 27.1 versus 28.9 years; mean weight, 62.8 versus 62.2 kg; and mean body mass index, 23.0 versus 22.2 kg/m(2) in the dapagliflozin 5- and 10-mg studies, respectively. In both doses, dapagliflozin was rapidly absorbed (T-max, <= 1.5 h), accumulation (defined as the geometric mean ratio of AUC(tau) at day 10 to AUC(tau) at day 1) after multiple dosing was minimal (<1.13 fold), and elimination half-life was 10 to 12 h. D3OG showed a slightly longer median T-max (<= 2 h) but a similar plasma concentration time profile and half-life compared with dapagliflozin. The majority of D3OG (up to 69.7% of the dapagliflozin dose) was excreted in urine, while <= 1.9% of dapagliflozin was excreted unchanged in urine. Over a 24-hour period and at steady state (day 10), urinary glucose excretion values were 28.1 and 41.1 g with dapagliflozin 5 and 10 mg, respectively. Dapagliflozin was generally well tolerated; one dapagliflozin 10 mg treated subject discontinued the study because of a serious adverse event (bronchitis) considered by the investigator as unrelated to dapagliflozin dosing.Conclusions: Pharmacokinetic and pharmacodynamic characteristics following single- and multiple-dose dapagliflozin 5 and 10 mg oral administration in healthy Chinese subjects were as predicted from previous studies and were similar to findings observed in non-Chinese healthy subjects. Dapagliflozin dosing was well tolerated. The clinically recommended dapagliflozin dose of 10 mg once daily is expected to be appropriate in patients of Chinese ethnicity; results from an efficacy and tolerability study in Chinese patients with T2DM are awaited. (C) 2013 Elsevier HS Journals, Inc. All rights reserved.

Pharmacokinetics of Compound Pioglitazone Hydrochloride and Glimepiride Tablet in Healthy Chinese Volunteers

Pharmacokinetics and Safety of Pitavastatin Calcium Tablets in Chinese Healthy Volunteers after a Single Oral Dose Administration

Bioequivalence of Glipizide Controlled-Release Tablets in Chinese Healthy Volunteers

[Pharmacokinetics and Relative Bioavailability of Ziprasidone Tablets in Chinese Healthy Volunteers].

Pharmacokinetic characteristics of single-dose pidotimod injection in Chinese healthy volunteers

Effects of Functional CYP2C8,CYP2C9,CYP3A5,and ABCB1 Genetic Variants on the Pharmacokinetics of Insulin Sensitizer Pioglitazone in Chinese Han Individuals

Pharmacokinetics and relative bioavailability of compound metformin hydrochloride tablet in healthy volunteers

Pharmacokinetics and bioequivalance of domestic compound glibenclamide and metformin in chinese healthy volunteers

Pharmacokinetics of Compound Telmisartan Tablets in Chinese Healthy Volunteers

Pharmacokinetics Study of rhGLP1(7-36) in Type 2 Diabetes Patients

Biochemical alterations and liver toxicity analysis with pioglitazone in healthy subjects

Effects of Food and Multiple‐dose Administration on the Pharmacokinetic Properties of HR20033, a Sustained‐release Formulation of Henagliflozin and Metformin for the Treatment of Diabetes, in Healthy Chinese Volunteers

Evaluation of the Bioequivalence and Pharmacokinetics of Two Formulations of Gliclazide in Healthy Chinese Volunteers Using Population Pharmacokinetic Approach

Pharmacokinetics of Dapoxetine Hydrochloride in Chinese Healthy Male Volunteers

Pharmacokinetics of compound famotidine chewing tablets in Chinese healthy volunteers after a single oral dose administration

Pharmacokinetics, Safety and Tolerability of Chiglitazar, A Novel Peroxisome Proliferator-Activated Receptor (PPAR) Pan-Agonist, in Healthy Chinese Volunteers: A Phase I Study

Randomized,double-blind,double-dummy,controlled clinical trial of pioglitazone/metformin in the treatment of type 2 diabetes

Multi-center Study of Safety and Efficacy Evalution of Glimepiride in Type 2 Diabetic Patients

Pharmacokinetic and Pharmacodynamic Properties of Single- and Multiple-Dose of Dapagliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects.

Efficacy and Safety of Glimepiride As Initial Treatment in Chinese Patients with Type 2 Diabetes Mellitus

Bioequivalence of Rosiglitazone Tartrate Tables and Rosiglitazone Maleate Tables in Healthy Volunteers